Valneva SE Terminates Vaccine Deal with Serum Institute

MT Newswires Live01-01

Valneva SE (VALN) said Wednesday it has ended its licensing deal with Serum Institute of India for Valneva's chikungunya vaccine.

The company said this decision is meant to increase vaccine distribution in areas at high-risk of chikungunya, in line with Valneva's EU-supported funding agreement with the Coalition for Epidemic Preparedness Innovations, or CEPI.

Valneva plans to fully control the supply chain and commercialization of the vaccine to enable quick access in high-risk regions.

Previously, the company's single-dose vaccine for chikungunya, Ixchiq, was authorized by the U.S. Food and Drug Administration in November 2023 but suspended in August, due to safety concerns.

Shares of Valneva rose past 4% in recent trading.

Price: 8.70, Change: +0.35, Percent Change: +4.19

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2600470684?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-01 02:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2600470684","market":"sh","top_or_hot":-1,"title":"Valneva SE Terminates Vaccine Deal with Serum Institute","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/INRLF\">Valneva SE</a> (VALN) said Wednesday it has ended its licensing deal with Serum Institute of India for Valneva's chikungunya vaccine.</p><p>The company said this decision is meant to increase vaccine distribution in areas at high-risk of chikungunya, in line with Valneva's EU-supported funding agreement with the Coalition for Epidemic Preparedness Innovations, or CEPI.</p><p>Valneva plans to fully control the supply chain and commercialization of the vaccine to enable quick access in high-risk regions.</p><p>Previously, the company's single-dose vaccine for chikungunya, Ixchiq, was authorized by the U.S. Food and Drug Administration in November 2023 but suspended in August, due to safety concerns.</p><p>Shares of Valneva rose past 4% in recent trading.</p><p>Price: 8.70, Change: +0.35, Percent Change: +4.19</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Valneva SE Terminates Vaccine Deal with Serum Institute</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nValneva SE Terminates Vaccine Deal with Serum Institute\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-01 02:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/INRLF\">Valneva SE</a> (VALN) said Wednesday it has ended its licensing deal with Serum Institute of India for Valneva's chikungunya vaccine.</p><p>The company said this decision is meant to increase vaccine distribution in areas at high-risk of chikungunya, in line with Valneva's EU-supported funding agreement with the Coalition for Epidemic Preparedness Innovations, or CEPI.</p><p>Valneva plans to fully control the supply chain and commercialization of the vaccine to enable quick access in high-risk regions.</p><p>Previously, the company's single-dose vaccine for chikungunya, Ixchiq, was authorized by the U.S. Food and Drug Administration in November 2023 but suspended in August, due to safety concerns.</p><p>Shares of Valneva rose past 4% in recent trading.</p><p>Price: 8.70, Change: +0.35, Percent Change: +4.19</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VALN","symbol_name":"Valneva SE","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2600470684","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2600470684","pubTimestamp":1767207245,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Valneva SE  said Wednesday it has ended its licensing deal with Serum Institute of India for Valneva's chikungunya vaccine.The company said this decision is meant to increase vaccine distribution in areas at high-risk of chikungunya, in line with Valneva's EU-supported funding agreement with the Coalition for Epidemic Preparedness Innovations, or CEPI.Valneva plans to fully control the supply chain and commercialization of the vaccine to enable quick access in high-risk regions.Previously, the company's single-dose vaccine for chikungunya, Ixchiq, was authorized by the U.S. Food and Drug Administration in November 2023 but suspended in August, due to safety concerns.Shares of Valneva rose past 4% in recent trading.Price: 8.70, Change: +0.35, Percent Change: +4.19","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VALN":"Valneva SE","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"Valneva SE终止与血清研究所的疫苗协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VALN":1},"content_text":"Valneva SE (VALN) said Wednesday it has ended its licensing deal with Serum Institute of India for Valneva's chikungunya vaccine.The company said this decision is meant to increase vaccine distribution in areas at high-risk of chikungunya, in line with Valneva's EU-supported funding agreement with the Coalition for Epidemic Preparedness Innovations, or CEPI.Valneva plans to fully control the supply chain and commercialization of the vaccine to enable quick access in high-risk regions.Previously, the company's single-dose vaccine for chikungunya, Ixchiq, was authorized by the U.S. Food and Drug Administration in November 2023 but suspended in August, due to safety concerns.Shares of Valneva rose past 4% in recent trading.Price: 8.70, Change: +0.35, Percent Change: +4.19","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2600470684","isCrawlerRequest":true}